Executive Committee

Forging the way for tomorrow’s innovations today

Genmab has a strong and experienced leadership team in place, who together lead more than 2,000 employees to achieve our vision.

With their passion for innovation, deep understanding of the antibody field and proven business acumen, our senior leaders bring their combined know-how to guide the company’s continued growth trajectory.

Learn more about our senior leaders by clicking on their names.

Jan G. J. van de Winkel, Ph.D.

President & Chief Executive Officer

Dr. van de Winkel is a co-founder of Genmab and served as President, Research & Development and Chief Scientific Officer of the company until his appointment as President & Chief Executive Officer in 2010. Dr. van de Winkel has more than 25 years of experience in the therapeutic antibody field and served as Vice President and Scientific Director of Medarex Europe prior to Genmab. He is the author of over 300 scientific publications and has been responsible for over 150 patents and pending patent applications.

Dr. van de Winkel holds a professorship of immunotherapy at Utrecht University. He is chairman of the board of directors of Hookipa Pharma and a member of the board of directors of LEO Pharma. He holds M.S. and Ph.D. degrees from the University of Nijmegen.

Dr. van de Winkel is a registered manager of Genmab with the Danish Business Authority.



Anthony Pagano

Executive Vice President & Chief Financial Officer

Mr. Pagano joined Genmab in 2007, was appointed Senior Vice President in 2011 and became the Executive Vice President and Chief Financial Officer effective March 1, 2020. Prior to joining Genmab, Mr. Pagano was Corporate Controller and Senior Director of Business Planning at NovaDel Pharma, a publicly traded specialty pharmaceutical company. He started his career at KPMG LLP, reaching the position of Manager, where he provided audit and M&A consulting services to clients ranging from start-ups to Fortune 500s in a broad range of industries.

He is a Certified Public Accountant and received a B.S. in Accounting from The College of New Jersey, as well as an M.B.A. from the Stern School of Business at New York University.

Mr. Pagano is a registered manager of Genmab with the Danish Business Authority.



Judith Klimovsky, M.D.

Executive Vice President & Chief Development Officer

Dr. Klimovsky joined Genmab in 2017 and is a recognized drug developer with more than 20 years of experience in R&D leadership roles in big pharma. She has successfully led the development of key cancer drugs at both Bristol Myers Squibb and Novartis, from early clinic through late-stage development and approval including ixabepilone (BMS), ASA404, MEK162, LGX818 and Afinitor (Novartis). During the span of her career, she has led global development organizations of over 450 people.

Previously, Dr. Klimovsky served in various hematology clinical practice positions in Buenos Aires, Argentina. Dr. Klimovsky earned her M.D. from the Buenos Aires University School of Medicine. As a medical doctor, she also brings skills and experience from working as a clinician in hospital environments.

Dr. Klimovsky has been a member of the Board of Directors of Bio-Techne since April 2024.


Argentinian (U.S. Citizen)

Anthony Mancini

Executive Vice President & Chief Operating Officer

Mr. Mancini joined Genmab in March 2020 as Executive Vice President and Chief Operating Officer. He is responsible for ensuring Genmab brings its innovative and differentiated medicines to patients around the world. He leads Genmab’s Commercialization, Business & Corporate Development as well as Information Technology /Digital functions.

Prior to joining Genmab, Mr. Mancini served in a variety of strategic and operational leadership roles over a 24-year career at Bristol Myers Squibb (BMS) including the leadership of BMS’ US Innovative Medicines Unit, a cross-functional team of over 1100 people, across multiple therapeutic areas including Immunology & Cardiovascular diseases.

He holds a Bachelor of Science in Biochemistry from the University of Ottawa, Canada, an M.B.A. from Clemson University, South Carolina, USA, and participated in the General Management Program, CEDEP at INSEAD, Fontainebleau, France.


Canadian and Italian (U.S. Citizen)

Tahamtan Ahmadi, M.D., Ph.D.

Executive Vice President & Chief Medical
Officer, Head of Experimental Medicines

Dr. Ahmadi joined Genmab in 2017 and became the Executive Vice President and Chief Medical Officer, Head of Experimental Medicines effective March 1, 2021. He holds an M.D. from the University of Cologne (Germany) and a Ph.D. from the University of Freiburg (Germany) and has expertise in translational research, strategic product development, global regulatory submissions and clinical development. Prior to joining Genmab, Dr. Ahmadi was head of experimental medicine and early development oncology at Janssen and a member of the Senior Leadership Team for Oncology.

During his time at Janssen, he led the global development of daratumumab including clinical R&D and medical affairs strategy across indications and was instrumental in the clinical development and initial FDA NDA submission for Ibrutinib. Prior to joining Janssen, Dr. Ahmadi was a faculty member of the Department of Hematology and Oncology at the University of Pennsylvania. Dr. Ahmadi is an author on a number of scientific articles that have been published in journals such as NEJM, Lancet, JCO and Blood, among others.


Iranian-German (U.S. Citizen)

Birgitte Stephensen, M.S.

Executive Vice President & Chief Legal Officer

Ms. Stephensen joined Genmab in 2002 and became the Executive Vice President & Chief Legal Officer effective March 1, 2022. Ms. Stephensen has extensive experience from both private practice and industry working with intellectual property and legal matters within the pharmaceutical and biotech field. In her tenure at Genmab, she has been instrumental in leading the company’s intellectual property rights and legal strategy. Ms. Stephensen passed the European Qualifying Examination as European Patent Attorney. She earned an M.S. from the Danish University of Pharmaceutical Sciences.



Christopher Cozic

Executive Vice President & Chief People Officer

Mr. Cozic joined Genmab in 2017 and became the Executive Vice President & Chief People Officer effective March 1, 2022. Mr. Cozic has extensive experience as a global human resource executive in strategic leadership, organization design, human resource management, policy development, employee relations, organizational development, and a heavy concentration in all aspects of corporate growth and expansion.

Prior to joining Genmab, Mr. Cozic held leadership roles in the biopharma and telecommunications industries. He received his bachelor’s degree in English and Communications from Quinnipiac University and also attained Senior and Global Professional Human Resource (SPHR and GPHR) certifications.



Martine J. van Vugt, Ph.D.

Executive Vice President & Chief Strategy Officer

Dr. van Vugt started her professional career at Genmab in 2001 and was appointed Executive Vice President in 2023 and is currently responsible for Corporate Strategy, Corporate Development, Business Development and Licensing and Alliance Management. She has been active in business development operations since 2011. From 1998 until joining Genmab in 2001 she studied dendritic cell vaccination therapy as a post-doctoral fellow. Dr. van Vugt holds an M.S. from the University of Wageningen and a Ph.D. from Utrecht University.



Want to get the latest stock information and news about Genmab?

Start here

  • Sound corporate governance

    Our corporate governance is at the center of everything we do

    Learn more

  • Being socially responsible

    We are building a sustainable company through business-driven CSR

    Learn about our CSR

  • Turning insights into medicine

    See the results of innovation that is rooted in science

    Explore the pipeline

You are now leaving to go to our collaborator’s website. If you continue, we encourage you to read the website’s privacy and cookie policy.